A5077083856- Acute Myeloid Leukemia Research
- Histone Deacetylase Inhibitors Research
- Chronic Myeloid Leukemia Treatments
- Hematopoietic Stem Cell Transplantation
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Acute Lymphoblastic Leukemia research
- Multiple Myeloma Research and Treatments
- Polyomavirus and related diseases
- Cytomegalovirus and herpesvirus research
- Viral-associated cancers and disorders
- Chronic Lymphocytic Leukemia Research
- Bone and Joint Diseases
- Retinoids in leukemia and cellular processes
- Neutropenia and Cancer Infections
- Lymphoma Diagnosis and Treatment
- Epigenetics and DNA Methylation
- Synthetic Organic Chemistry Methods
- Neonatal Health and Biochemistry
- Autophagy in Disease and Therapy
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Hemoglobinopathies and Related Disorders
- Circular RNAs in diseases
- CNS Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
Nanfang Hospital
2016-2025
Southern Medical University
2016-2025
The University of Texas MD Anderson Cancer Center
2017-2024
Affiliated Hospital of Southwest Medical University
2024
Aptose Biosciences (United States)
2023
Stony Brook University Hospital
2015
Stony Brook University
2015
Augusta University
2009
Peking Union Medical College Hospital
2009
Chinese Academy of Medical Sciences & Peking Union Medical College
2009
Abstract Background Relapsed or refractory acute myeloid leukemia (R/R AML) has a dismal prognosis. The aim of this study was to investigate the activity and tolerability venetoclax combined with azacitidine plus homoharringtonine (VAH) regimen for R/R AML. Methods This phase 2 trial done at ten hospitals in China. Eligible patients were AML (aged 18–65 years) an Eastern Cooperative Oncology Group performance status 0–2. Patients received (100 mg on day 1, 200 2, 400 days 3–14) (75 mg/m 1–7)...
We recently demonstrated that blood-brain barrier permeabilization using mannitol enhances the therapeutic efficacy of systemically administered human umbilical cord blood (HUCB) by facilitating entry neurotrophic factors from periphery into adult stroke brain. Here, we examined whether same manipulation approach increases effects intravenously delivered HUCB in a neonatal hypoxic-ischaemic (HI) injury model. Seven-day-old Sprague-Dawley rats were subjected to unilateral HI and then at day 7...
We conducted a prospective, randomized, open-label, multicenter study to compare busulfan plus fludarabine (BuFlu) with cyclophosphamide (BuCy) as the conditioning regimen in allogeneic hematopoietic stem cell transplantation (allo-HSCT) for acute myeloid leukemia (AML) first complete remission (CR1). Totally 108 AML-CR1 patients undergoing allo-HSCT were randomized into BuCy (busulfan 1.6 mg/kg, q12 hours, -7 ~ -4d; 60 mg/kg.d, -3 -2d) or BuFlu -5 -2d; 30 mg/m2.d, -6 group. Hematopoietic...
Poor graft function (PGF) is a refractory complication that occurs after allogeneic hematopoietic stem cell transplantation (allo-HSCT). In the present study, we prospectively evaluated efficacy and safety of mesenchymal cells (MSCs) expanded from bone marrow third-party donor to patients with PGF allo-HSCT. Twenty (7 primary 13 secondary PGF) received MSCs (1 × 10(6)/kg) one three times at 28-day intervals. Seventeen were responsive MSCs, whereas not. Within first 100 days MSC treatment,...
Abstract Background Intensified conditioning regimens (increasing the intensity of standard myeloablative conditioning) for hematological malignancies in allogeneic hematopoietic stem cell transplantation (allo-HSCT) could reduce relapse rate underlying disease, but it might simultaneously increase transplant-related mortality including infections. To explore whether intensified affected Epstein-Barr virus (EBV) and cytomegalovirus (CMV) infections, 185 patients undergoing allo-HSCT were...
Abstract Background The heterogeneity of relapsed or refractory (R/R) acute myeloid leukemia (AML) leads to no response venetoclax (VEN)–based therapy in more than half the patients. Genetic characteristics are considered important predictors for treatment adults with AML. However, association genetic outcomes receiving VEN‐based is incompletely understood R/R Objective To evaluate efficacy VEN combined hypomethylating agents (HMA) and identify potential Methods A total 150 AML patients...
Existing standard techniques for erythrocyte (RBC) lifespan measurement, such as quantitation of labeling with isotopes or biotin, are cumbersome and time-consuming. Given that endogenous CO originates mainly from degraded RBCs, a team lead by Levitt developed breath test to enable more efficient RBC estimation. The purpose this study was evaluate the reliability Levitt's method our newly automatic instrument. measurements conducted were in 109 healthy subjects 91 patients chronic hemolytic...
Strategies to overcome resistance FMS-like tyrosine kinase 3 (FLT3)-targeted therapy in acute myeloid leukemia (AML) are urgently needed. We identified autophagy as one of the mechanisms, induced by hypoxia and bone marrow microenvironment via activation Bruton (BTK). Suppressing autophagy/BTK sensitized FLT3- mutated AML FLT3 inhibitor-induced apoptosis. Furthermore, co-targeting FLT3/BTK/aurora kinases with a novel multikinase inhibitor CG-806 (luxeptinib) profound apoptosis FLT3-mutated...
Abstract Background Patients with relapsed or refractory acute myeloid leukemia (R/R AML) and FLT3 ‐internal tandem duplication ( FLT3‐ITD ) respond infrequently to salvage chemotherapy. Objective To investigate the efficacy of sorafenib plus triplet therapy venetoclax, azacitidine, homoharringtonine (VAH) as a in this population. Methods This multicenter, single‐arm, phase 2 study was conducted at 12 hospitals across China. Eligible patients had R/R AML (aged 18–65 years) who were treated...
Epstein-Barr virus (EBV) infection may result in a spectrum of diseases recipients transplant. The aim this study is to investigate the incidence, clinical characteristics, and prognosis EBV-associated allogeneic hematopoietic stem cell transplantation (allo-HSCT).A total 263 undergoing allo-HSCT were prospectively enrolled. blood EBV-DNA loads regularly monitored by quantitative real-time polymerase chain reaction.The 3-year cumulative incidence diseases, posttransplantation...
<p>Supplementary Figure S4. Survival outcomes in VA and VAH patients depending on FLT3-ITD mutation.</p>
<p>Supplementary Figure S5. Incorporating HHT to overcome VEN resistance.</p>
<div>AbstractPurpose:<p>We investigated whether homoharringtonine (HHT) added to venetoclax plus azacitidine (VA) could improve outcomes and counteract the negative effects of genetic patterns in patients with relapsed/refractory acute myeloid leukemia (RR-AML).</p>Experimental Design:<p>A multicenter retrospective cohort study response VA HHT (VAH) versus regimens as salvage treatment RR-AML was performed. The endpoints were rates composite complete remission,...
<p>Supplementary Figure S3. Prognostic effect of VA and VAH on OS in genetic subgroups.</p>
<p>Supplementary Figure S2. Treatment response rates by co-mutations.</p>
<p>Supplementary Figure S1. Analysis of pairwise co-mutation and mutual exclusivity in the top 20 most frequently detected gene mutations.</p>
Background: We aim to analyze the efficacy and safety of Venetoclax (Ven) added cladribine + cytarabine granulocyte colony-stimulating factor (G-CSF) ± idarubicin or mitoxantrone (CLAG Ida/Mito) regimen as a salvage treatment relapsed/refractory acute myeloid leukemia (RR-AML). Methods: A single-center, retrospective, cohort study was performed. Patients with RR-AML, being treated CLAG Ida/Mito versus without Ven, were retrospectively studied. The endpoints this evaluate rate composite...